Elgebaly, A. S., Ashal, G. E., Elfil, M., & Menshawy, A. (2017). Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clinical and Applied Thrombosis/Hemostasis, 23(8), 928-937 - https://pubmed.ncbi.nlm.nih.gov/27572890/
Wong, R. S., Saleh, M. N., Khelif, A., Salama, A., Portella, M. S. O., Burgess, P., & Bussel, J. B. (2017). Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood, The Journal of the American Society of Hematology, 130(23), 2527-2536 - https://pubmed.ncbi.nlm.nih.gov/29042367/
Bussel, J. B., Cheng, G., Saleh, M. N., Psaila, B., Kovaleva, L., Meddeb, B., ... & Jenkins, J. M. (2007). Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357(22), 2237-2247 - https://pubmed.ncbi.nlm.nih.gov/18046028/
Saleh, M. N., Bussel, J. B., Cheng, G., Meyer, O., Bailey, C. K., Arning, M., & Brainsky, A. (2013). Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, The Journal of the American Society of Hematology, 121(3), 537-545. - https://pubmed.ncbi.nlm.nih.gov/23169778/
Cheng, G., Saleh, M. N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., ... & Bussel, J. B. (2011). Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet, 377(9763), 393-402.
Bussel, J. B., de Miguel, P. G., Despotovic, J. M., Grainger, J. D., Sevilla, J., Blanchette, V. S., ... & Bakshi, K. K. (2015). Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. The Lancet Haematology, 2(8), e315-e325 - https://pubmed.ncbi.nlm.nih.gov/26688484/